NCT07091682View on ClinicalTrials.gov

Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 18, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2031

Conditions
Coronary Artery DiseaseAtherosclerosis of Coronary ArteryMyocardial IschemiaIschemic Heart DiseaseAcute Coronary SyndromesAngina Pectoris
Interventions
DEVICE

Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold

Subjects with symptomatic coronary artery disease who qualify for percutaneous coronary intervention (PCI) will be treated with a sirolimus eluting resorbable coronary Magnesium scaffold

Trial Locations (3)

1002

RECRUITING

Pauls Stradins Clinical University Hospital, Riga

37126

NOT_YET_RECRUITING

Azienda Ospedaliera Universitaria Integrata Verona, Verona

87509

RECRUITING

Klinikverbund Allgäu gGmbH, Immenstadt im Allgäu

Sponsors

Lead Sponsor

Biotronik AG
All Listed Sponsors
lead

Biotronik AG

INDUSTRY

NCT07091682 - Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | Biotech Hunter | Biotech Hunter